WO2021256540A1 - ウイルス不活化製剤 - Google Patents

ウイルス不活化製剤 Download PDF

Info

Publication number
WO2021256540A1
WO2021256540A1 PCT/JP2021/023059 JP2021023059W WO2021256540A1 WO 2021256540 A1 WO2021256540 A1 WO 2021256540A1 JP 2021023059 W JP2021023059 W JP 2021023059W WO 2021256540 A1 WO2021256540 A1 WO 2021256540A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
test
fumaric acid
acid
inactivating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/023059
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
一彦 奥薗
繁 土居
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nishinihon Nagase Co Ltd
Daiichi Seimo Co Ltd
Original Assignee
Nishinihon Nagase Co Ltd
Daiichi Seimo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nishinihon Nagase Co Ltd, Daiichi Seimo Co Ltd filed Critical Nishinihon Nagase Co Ltd
Priority to JP2021561857A priority Critical patent/JP7509380B2/ja
Publication of WO2021256540A1 publication Critical patent/WO2021256540A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/02—Acyclic compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/06—Unsaturated carboxylic acids or thio analogues thereof; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the present invention relates to a virus inactivating preparation such as influenza virus, norovirus, and new coronavirus (SARS-CoV2).
  • virus inactivating preparation such as influenza virus, norovirus, and new coronavirus (SARS-CoV2).
  • viruses include enveloped viruses (eg, influenza virus, coronavirus [including new coronavirus (SARS-CoV2)], RS virus, SARS virus, etc.) and non-enveloped non-enveloped virus (eg, influenza virus, SARS virus, etc.).
  • enveloped viruses eg, influenza virus, coronavirus [including new coronavirus (SARS-CoV2)], RS virus, SARS virus, etc.
  • non-enveloped non-enveloped virus eg, influenza virus, SARS virus, etc.
  • adenovirus, norovirus, rotavirus, enterovirus, etc. are present.
  • Norovirus is an non-enveloped RNA virus (hereinafter referred to as "norovirus") classified into Caliciviridae and Norovirus genus, and is alcohol (ethanol, isopropanol, etc.), heat, acidic (stomach acid, etc.), Alternatively, it has a strong resistance to drying and the like.
  • the incubation period is thought to be 1 to 2 days, and the main symptoms of nausea, vomiting, and diarrhea appear, but may be accompanied by abdominal pain, headache, fever, chills, muscle pain, sore throat, and malaise.
  • Oral infection is known as one of the infection routes of norovirus, etc., and infection is established by ingesting food, water, etc. contaminated with norovirus, etc. Therefore, in places such as restaurants, school lunch facilities, and factories where food is cooked and processed, it is required to prevent food, water, and the like from being contaminated by norovirus and the like.
  • a method for inactivating a virus such as norovirus for example, a method using a chlorine bleach (sodium hypochlorite or the like) is known, but the chlorine bleach has a corrosive effect on metals. It has an irritating effect on the skin and a bleaching effect on clothing. Therefore, there is a drawback that its use is restricted, and in particular, it is not appropriate to use these chemicals on the hands, tableware, countertops, cooking utensils, etc. of workers in consideration of safety for the human body. It was not appropriate to let them come into direct contact with food. Therefore, agents and methods that are safe for the human body and can inactivate norovirus and the like have been desired.
  • a chlorine bleach sodium hypochlorite or the like
  • FCV feline calicivirus
  • MNV murine norovirus
  • influenza is an acute respiratory infection caused by the influenza virus, and different types of influenza are prevalent all over the world every year.
  • influenza virus infection is prevented by vaccination or treated with drugs such as neuraminidase inhibitors, but there is a problem that their effects differ significantly depending on the type of influenza virus. ..
  • drugs have problems such as side effects and the emergence of resistant viruses.
  • safe and secure influenza virus inactivating agents that are less harmful to the human body, such as those contained in foods and drinks, are eagerly desired. ing.
  • an inactivating agent or the like that can inactivate the above-mentioned virus, for example, 1) (A) 35 to 75% by mass of lower alcohol, (B) (b1) organic acid and its alkali metal salt, and / or (b2) inorganic acid and its alkali metal salt 0.05 to 10% by mass. (C) Contains 0.05 to 5% by mass of at least one nonionic surfactant selected from monoglycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, and sucrose fatty acid ester.
  • A) ethanol 50-70% by weight of (A) ethanol, and (B) organic acids (apple acid, lactic acid, citric acid, tartaric acid, salicylic acid, gluconic acid, adipic acid, phytic acid, acetic acid, fumaric acid, succinic acid, At least one selected from the group consisting of ascorbic acid, sorbic acid, benzoic acid, propionic acid, and maleic acid), at least one selected from the group consisting of (these) organic acid salts and ethanolamines.
  • a disinfectant solution for norovirus and the like which contains 0.05 to 4.50% by weight and has a pH of 6 to 12, and further contains 0.20 to 0.30% by weight of (C) glycerin fatty acid ester.
  • Disinfectant (see, for example, Patent Document 2), 3) Contact a composition consisting of an aqueous solution containing ethanol and acid as an active ingredient and having a pH in the range of 2.5 to 5.0 with a substance containing suspected calicivirus and a protein.
  • a method for inactivating feline calicivirus in the presence of a protein (see, for example, Patent Document 3). 4) (a) The ethanol concentration is 65 to 75% by weight, (b) the content of glycerin fatty acid ester is 0.03 to 0.15% by weight, and (c) the content of lactic acid or a salt thereof is 1.
  • Agents for viruses, antibacterial and antifungal agents see, eg, Patent Document 4), 5)
  • malic acid, lactic acid, phosphoric acid, tartaric acid, adipic acid is at least one selected from the group consisting of succinic acid, and phytic acid, the type of the cation and the anion, K + and SO 4 2-of combination, Fe 2+ and SO 4 2-combinations of, Cu 2+ and SO 4 2-combinations of, K + and Al 3+ and SO 4 2-combinations of, NH 4 + and Al 3+ and SO 4 2-a combination of, Na + and NO 3 - in combination, NH 4 + and NO 3 - in combination, Na + and NO 2 - in combination, K + and NO 2 - in combination, NH 4 + and NO 2 - combination of, Na + and SCN - combination, or, Na + and I - viral inactivating agent which is a combination of (e.g., see Patent Document 5), 6) A virus inactivating agent containing ethanol, a carbonate (at least one selected from the group consisting of sodium carbonate, potassium carbonate and ammonium carbon
  • Patent Documents 1 to 6 disclose the proximity technique of the present invention in that ethanol, various acids and the like are used, but these are technical ideas (configuration and its peculiarity) with the present invention in the following points and the like. The action and effect) are different.
  • 35 to 75% by mass of ethanol (95% of the amount of active ingredient treated as a dangerous substance) as a lower alcohol and 0.05 to 10 of citric acid or a salt thereof as an organic acid are used.
  • a bactericidal disinfectant composition containing% by mass, monoglycerin fatty acid ester, polyglycerin fatty acid ester, etc., and the pH (25 ° C.) of the undiluted solution of the composition is set in the range of 8 to 12 in the high alcohol range. It is a product, does not use fumaric acid used in the present invention, has a high concentration of ethanol, and has an alkaline pH, so that there are problems such as rough hands.
  • Patent Document 2 there is a description that 50 to 70% by weight of ethanol and fumaric acid can be used in combination as an organic acid, but there is no support for the examples, and there is a description that fumaric acid alone can inactivate the virus.
  • Patent Documents 3 to 6 contain a combination of ethanol and an acid (citric acid, lactic acid, etc.), and further contain a carbonate, a cation, an anion, etc. in each predetermined concentration range. There is no description or suggestion of, and the technical idea is different from that of the present invention.
  • ethanol has been used as rubbing alcohol or the like, and as described in each of the above patent documents, it has been used in combination with other components, but when the alcohol concentration is 60% by mass or more, in Japan. It falls under the category of dangerous goods stipulated in the Fire Service Act, and it is necessary to be careful in its handling, and when storing and handling a certain amount or more, notification and application are required.
  • fumaric acid is used as an acidulant for food additives and has a very strong bactericidal activity among organic acids, so it is used for cleaning foods (vegetables, etc.) and sterilizing and cleaning tank lines of food factories.
  • fumaric acid itself can be inactivated against influenza virus, norovirus, and the new coronavirus (SARS-CoV2).
  • Japanese Unexamined Patent Publication No. 2009-173641 Japanese Unexamined Patent Publication No. 2014-19659 (Claims, Examples, etc.) Japanese Unexamined Patent Publication No. 2014-129372 (Claims, Examples, etc.) JP-A-2019-73453 (Claims, Examples, etc.) JP-A-2019-156810 (Claims, Examples, etc.) JP-A-2019-182761 (Claims, Examples, etc.)
  • the present invention is intended to solve the above-mentioned problems of the prior art and the current situation, and is excellent in handleability, odorless, safe and efficient, influenza virus, norovirus, and new coronavirus (SARS-CoV2). It is an object of the present invention to provide a virus inactivating preparation capable of realizing the inactivation of).
  • the present inventors have selected fumaric acid as an influenza virus, norovirus, and new coronavirus (SARS-CoV2) among the organic acids used as acidulants for foods.
  • SARS-CoV2 new coronavirus
  • the virus inactivating preparation of the above object could be obtained, and the virus inactivating preparation of the present invention was completed. That is, in the first invention of the present invention, the virus inactivating preparation is characterized by containing fumaric acid as a main component, and in the second invention, it is characterized by containing fumaric acid and ethanol.
  • the content of the fumaric acid is preferably 0.005 to 1% by mass, and the content of the ethanol is preferably 50% by mass or less.
  • the pH of the virus inactivating agent is preferably 2.0 to 5.5.
  • the virus inactivating agent preferably contains at least one selected from glycerin fatty acid ester, polyglycerin fatty acid ester, xanthan gum, sodium benzoate, potassium sorbate, polylysine, dehydroacetic acid and sodium dehydroacetate.
  • the virus inactivating agent it is preferable that the virus that can be inactivated is influenza virus, feline calicivirus, and new coronavirus (SARS-CoV2).
  • a virus inactivating preparation that is easy to handle, is odorless, and can safely and efficiently inactivate influenza virus, norovirus, and new coronavirus (SARS-CoV2).
  • SARS-CoV2 new coronavirus
  • the virus-inactivated preparation of the present invention is characterized in that it contains fumaric acid as a main component in the first invention, and is characterized in that it contains fumaric acid and ethanol in the second invention. be.
  • the fumaric acid used is not particularly limited, but is preferably a volume average particle diameter of 30 ⁇ m or less, more preferably 15 ⁇ m or less, and particularly preferably 10 ⁇ m or less, and the fumaric acid commercially available as a raw material is pulverized by a dry or wet method. Then, the one having the above-mentioned preferable particle size is used. Further, it may be used that has been crystallized and taken out so as to have a preferable particle size at the time of raw material production.
  • the content of fumaric acid used is 0.005 to 1% by mass (hereinafter, “mass%” is simply referred to as “%”), more preferably 0.03 to 1% by mass, based on the total amount of the virus-inactivated preparation. It is desirable to set it to 0.6%. If the content of fumaric acid is less than 0.005%, the effect of the present invention may not be exhibited, while if it exceeds 1%, the solubility is not sufficient, which is not preferable.
  • the fumaric acid alone acts as an inactivating component against influenza virus and norovirus (substitute for feline calicivirus), but further, in terms of product stability and storage stability. Therefore, fumaric acid and ethanol can be used in combination.
  • the content of fumaric acid is the same as in the case of the above-mentioned fumaric acid alone (0.005 to 1%, preferably 0.01 to 0.6%) with respect to the total amount of the virus-inactivated preparation.
  • the ethanol content is preferably 50% or less, more preferably 5 to 40%, and particularly preferably 10 to 40%.
  • the pH of the virus-inactivated preparations of the first invention and the second invention is preferably 2.0 to 5.5, more preferably 2.2 to 4.0, from the viewpoint of antiviral effect. Is desirable.
  • the pH range (2.0 to 5.5) is adjusted by adjusting the content of fumaric acid, and when ethanol is used in combination, the content of ethanol is adjusted to further adjust the remaining water (remaining water (). It can be adjusted by the content of tap water, distilled water, ion-exchanged water, purified water, pure water, ultra-pure water, etc. It can be adjusted by adding it.
  • the virus inactivating preparations of the first invention and the second invention are preferably glycerin fatty acid ester, polyglycerin fatty acid ester, xanthan gum, from the viewpoint of solubilization, product stability, and antifungal effect. It preferably contains at least one selected from sodium benzoate, potassium sorbate, polylysine, dehydroacetic acid and sodium dehydroacetate. These ingredients are used as food additives, and their safety has been confirmed.
  • glycerin fatty acid ester The above-mentioned glycerin fatty acid ester, polyglycerin fatty acid ester, and xanthan gum take into consideration the poor solubility of fumaric acid (solubility in water: 25 ° C., 0.63 g / 100 mL), and disperse performance and dispersion stability in virus-inactivated preparations.
  • the total content is preferably 0.001 to 20%, more preferably 0.003 to 17.5%, based on the total amount of the virus-inactivating preparation. Is desirable.
  • an aqueous dispersion in which fumaric acid having a predetermined volume average particle size is dispersed in advance with the glycerin fatty acid ester, polyglycerin fatty acid ester, the dispersion stabilizer of xanthan gum or the like is used. It is preferable, and particularly preferably, the above-mentioned predetermined amount of fumaric acid having a volume average particle size of 10 ⁇ m or less, xanthan gum 0.01 to 5%, and glycerin fatty acid ester 0.025 to 12.5% with respect to the total amount of the composition.
  • an aqueous dispersion of fumaric acid containing the above-mentioned water is desirable to use an aqueous dispersion of fumaric acid containing the above-mentioned water as a balance.
  • the above-mentioned predetermined amount of fumaric acid having a volume average particle diameter of 10 ⁇ m or less the above-mentioned predetermined amount of ethanol, xanthan gum 0.01 to 5%, and glycerin fatty acid ester 0. It is desirable to use an aqueous dispersion of ethanol fumarate containing 025 to 12.5% and the balance of the above water.
  • the above-mentioned sodium benzoate, potassium sorbate, polylysine, dehydroacetic acid and sodium dehydroacetate are preservatives used in foods and cosmetics, and fumaric acid can be added by containing these components as necessary. It is possible to further realize antifungal measures and storage stability when used alone, and the total content is preferably 0.01 to 5%, more preferably 0.1, based on the total amount of the virus-inactivated preparation. It is desirable to set it to ⁇ 2%.
  • the virus inactivating preparations of the first invention and the second invention of the present invention configured in this way are excellent in handleability, and safely and efficiently inactivate influenza virus, norovirus, and new coronavirus (SARS-CoV2). realizable.
  • the virus inactivating agent of the present invention includes food factories, coffee shops, restaurants, hotels, taverns, school meals, central kitchens, kitchen tables such as supermarket backyards, hospitals / nursing facilities, and spaces, refrigerators, and storages of these facilities.
  • the virus inactivating agent of the present invention includes fibers such as masks, towels, sheets, cloths, tablecloths, curtains, white clothes, and clothing, or floorboards, tatami mats, walls, folds, chairs, tables, doors, kitchen equipment, etc.
  • a virus inactivating agent aqueous fumaric acid solution
  • spraying it and then drying it to fix fumaric acid and apply anti-virus processing.
  • a binder having a predetermined concentration such as acrylic, polyurethane or polyester can be used in combination (blended) with the virus inactivating agent.
  • fumaric acid is used as an acidulant for foods, and at the applied concentration, it has almost no acidity and is odorless, colorless and transparent, and can be applied to fresh products such as agricultural and marine products, and to the oral cavity, nasal cavity, and skin.
  • the method of using the virus inactivating agent is not particularly limited, but for example, the object is immersed in the virus inactivating agent, and the virus inactivating agent is applied or sprayed on the object (for example, trigger spray, dispenser spray, aerosol, etc.). , It may be naturally dried as it is, or it can be used by air-drying, wiping, etc.
  • the amount to be applied or sprayed on the object may be any amount as long as it can be applied or sprayed evenly on the object, and the amount is not particularly limited, but is, for example, about 1 to 20 mL.
  • the virus inactivating agent of the present invention can be impregnated into a non-woven fabric to form a virus inactivating material, and the virus can be efficiently inactivated by wiping it as a wet sheet.
  • Test Example 1 Examples 1 and 2
  • a virus inactivation test evaluation was performed by the following test method.
  • the pH values of the test samples 1 and 2 were measured using a pH meter HM-30G (manufactured by Toa DKK Corporation) at a liquid temperature of 25 ° C. (the same was also measured for Test Examples 2 and later described later).
  • test sample 1 (total amount 100%): Fumaric acid (volume average particle size is 10 ⁇ m, the same applies below) 0.3% Xanthan gum 0.002% Glycerin fatty acid ester 0.005% Water (purified water) 99.693% pH value 2.3
  • Composition of test sample 2 (total amount 100%): Fumaric acid 0.3% 50% ethanol Xanthan gum 0.002% Glycerin fatty acid ester 0.005% Water (purified water) 49.693% pH value 2.3
  • test samples 1 and 2 prepared above, antiviral test, specifically, 0.9 ml of each test sample solution and 0.1 ml of the test virus solution are mixed with the following test virus for 30 minutes (5 minutes). Let it stand still. Then, 9 ml of SCDLP was added to prepare a 10-fold diluted series, and the viral infectious titer after the action was determined by the plaque method. The smaller this number, the smaller the viral load.
  • Test virus 1 Feline calicivirus F-9 strain (feline calicivirus, ATCC VR-782) Host cell: CRFK cell (ATCC CCL-94)
  • Test virus 2 Influenza A virus (H3N2) A / Hong Kong / 8/68 strain (influenza A virus, ATCC VR-1679)
  • Host cell MDCK cell (ATCC CCL-34)
  • Test Examples 2 to 6 Next, in Test Examples 2 to 6 below, a virus inactivation test by comparing fumaric acid with other organic acids (citrate, lactic acid), a virus inactivation test by changing the concentration of fumaric acid, and fumaric acid and ethanol. A virus inactivation test by combined use, a virus inactivation test by changing the action time of fumaric acid, and a virus inactivation test against the new corona virus (SARS-CoV2) (the above antiviral activity value was calculated) were performed. If the concentration of fumaric acid or the like is the same in each sample solution, the description of the pH value will be omitted hereafter.
  • SARS-CoV2 new corona virus
  • Test Example 2 Example 3 and Comparative Examples 1 and 2
  • an antiviral test specifically, 0.9 ml of each test sample solution and 0.1 ml of the test virus solution are mixed with the following test virus and allowed to stand for 30 minutes. Then, 9 ml of SCDLP was added to prepare a 10-fold diluted series, and the virus infectivity value after the action was determined by the plaque method, and the antiviral activity value was determined.
  • Test virus Feline calicivirus F-9 strain (feline calicivirus, ATCC VR-782)
  • Host cell CRFK cell (ATCC CCL-94)
  • Test Example 3 Examples 4 to 6 and Comparative Example 3
  • an antiviral test specifically, 0.9 ml of each test sample solution and 0.1 ml of the test virus solution are mixed with the following test virus and allowed to stand for 30 minutes. Then, 9 ml of SCDLP was added to prepare a 10-fold diluted series, and the virus infectivity value after the action was determined by the plaque method, and the antiviral activity value was determined.
  • Test virus Influenza A virus (H3N2) A / Hong Kong / 8/68 strain (Influenza A virus, ATCC VR-1679)
  • Host cell MDCK cell (ATCC CCL-34)
  • Test Example 4 Examples 7 to 9
  • an antiviral test specifically, 0.9 ml of each test sample solution and 0.1 ml of the test virus solution are mixed with the following test virus and allowed to stand for 5 minutes. Then, 9 ml of SCDLP was added to prepare a 10-fold diluted series, and the virus infectivity value after the action was determined by the plaque method, and the antiviral activity value was determined.
  • Test virus Influenza A virus (H3N2) A / Hong Kong / 8/68 strain (influenza A virus, ATCC VR-1679) Host cell: MDCK cell (ATCC CCL-34) Test virus: Feline calicivirus F-9 strain (feline calicivirus, ATCC VR-782) Host cell: CRFK cell (ATCC CCL-94)
  • Test Example 5 Examples 10 to 17
  • the anti-virus test specifically 0.9 ml of each test sample solution and 0.1 ml of the test virus solution, were mixed with the test viruses shown in Tables 5 and 6 below for a certain period of time (15 seconds, 30 seconds, 60 seconds, 30 minutes) Let stand. Then, 9 ml of SCDLP was added to prepare a 10-fold diluted series, and the virus infectivity value after the action was determined by the plaque method, and the antiviral activity value was determined. These results are shown in Tables 5 and 6 below.
  • Test virus Influenza A virus (H3N2) A / Hong Kong / 8/68 strain (influenza A virus, ATCC VR-1679) Host cell: MDCK cell (ATCC CCL-34) Test virus: Feline calicivirus F-9 strain (feline calicivirus, ATCC VR-782) Host cell: CRFK cell (ATCC CCL-94)
  • Test Example 6 Examples 18 to 19
  • the effect on the new coronavirus (SARS-CoV-2) was tested by the following test method.
  • Test method 1) Add 10 ⁇ l of the virus solution to 90 ⁇ l of the solution having the composition shown in Table 7 below. 2) Let stand for 1 minute at room temperature. 3) Take 10 ⁇ l and suspend in 1000 ⁇ l cell culture medium (1/100 dilution). 4) Using a 96-well plate, serially dilute (TCID50 method) 5) After 3 days, the TCID50 value is measured and the viral load is calculated.
  • Virus name SARS-CoV-2 Virus strain name: JPN / TY / WK-521
  • GISAID EPI_ISL_408667 Reference: Matsuyama S et al., PNAS 2020, 117: 7001-7003 * Cultured cell line: VeroE6 / TMPRSS2 Culture medium: DMEM low Glc 10% FCS These results are shown in Table 7 below.
  • Example 20 The effect of fumaric acid-processed dough on influenza virus was tested by the following test method.
  • the polyester fabric manufactured by Color Dyeing Co., Ltd.
  • the polyester fabric is immersed in a 0.3% fumaric acid solution, squeezed (squeezing ratio 110 to 115%), blown and dried at 80 ° C., and adhered as shown in Table 8 below.
  • An amount of fumaric acid processed PET dough was prepared.
  • An antiviral test for influenza virus was carried out using this fumaric acid-processed dough.
  • the test method [Compliant with JIS L 1922 (ISO 18184)] is shown below.
  • Test method 1. 1. Inoculate each test product with the test virus solution (standard 200 ⁇ l / test product) Let stand at 2.25 ° C for 2 hours. (Control samples "immediately after inoculation" should be collected immediately without standing.) 3. 3. Add 20 ml of SCDLP medium to neutralize and recover the virus. 4. Create a 10-fold serial dilution series. 5. The prepared host cells are inoculated with the recovered stock solution and the diluted solution, respectively. After 6.1 hours, the agar medium is layered. After culturing for 7.4 days, the cells are fixed, agar is removed, and then staining is performed. 8. Visually measure the number of plaques to determine the infectious titer of the virus. 9.
  • Test virus Influenza A virus (H3N2) A / Hong Kong / 8/68 strain (influenza A virus, ATCC VR-1679)
  • Test Example 8 Example 21
  • the effect of fumaric acid-processed dough on feline calicivirus was tested.
  • the polyester fabric (color dyeing company Co., Ltd.) is immersed in a 0.6% fumaric acid solution, squeezed (squeezing ratio 110 to 115%), blown and dried at 80 ° C., and the fumaric acid shown in Table 6 below is used.
  • a processed PET fabric was created.
  • An antiviral test was carried out using a fumaric acid-processed dough, and an antiviral activity value was determined.
  • Feline calicivirus was used as the test virus, and the antiviral test was carried out in the same manner as in Test Example 7 above. These results are shown in Table 9 below.
  • Test virus Feline calicivirus F-9 strain (feline calicivirus, ATCC VR-782)
  • Test Example 9 Examples 22 to 26
  • the antiviral effect (combined with a binder) of the fumaric acid-processed dough was tested.
  • the fumaric acid + binder-processed polyester fabric (color dyeing company Co., Ltd.) shown in Table 7 above was prepared and evaluated for its antiviral effect.
  • Feline calicivirus was used as the test virus, and the antiviral test was carried out in the same manner as in Test Example 7 above. These results are shown in Table 10 below.
  • Test virus Influenza A virus (H3N2) A / Hong Kong / 8/68 strain (influenza A virus, ATCC VR-1679)
  • Staphylococcus aureus (Staphylococcus) A test was performed using aureus NBRC12732). The test method is based on "JIS L 1902: 2008 (ISO 20743), bacterial solution absorption method", and the washing method is based on "JIS L 0217, 103", using the following two types of dough. It was carried out by a quantitative test (calculation of antibacterial activity value) by the liquid absorption method. Fumaric acid-0.1% processed PET dough and fumaric acid-0.1% + mobile 963-3% processed PET dough were tested. The results are shown in Table 11 below. The antibacterial activity value A is evaluated as "an antibacterial effect is recognized" when 2.0 ⁇ A ⁇ 3.0 and "a strong effect is observed" when 3.0 ⁇ A.
  • the virus inactivating agent according to the present invention is norovirus, influenza virus, and new corona. It was confirmed that it had an inactivating effect on the virus (SARS-CoV2), and that it had a high anti-virus effect even in a short working time of 15 seconds. Considering the results of Test Examples 7 to 9 above, it was confirmed that both fumaric acid alone and the combined use of the binder had an antiviral activity value of 4.4 and had a high antiviral effect. It was found that the merit of using the above binder in combination is that the same effect can be exhibited even if the concentration of fumaric acid is lowered, and that it is a preferable embodiment even when washing resistance or the like is required.
  • a virus inactivating preparation that is easy to handle, odorless, and can safely and efficiently inactivate influenza virus, norovirus, and new coronavirus (SARS-CoV2) can be obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2021/023059 2020-06-19 2021-06-17 ウイルス不活化製剤 Ceased WO2021256540A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021561857A JP7509380B2 (ja) 2020-06-19 2021-06-17 ウイルス不活化製剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020105931 2020-06-19
JP2020-105931 2020-06-19
JP2021-039224 2021-03-11
JP2021039224 2021-03-11

Publications (1)

Publication Number Publication Date
WO2021256540A1 true WO2021256540A1 (ja) 2021-12-23

Family

ID=79268087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/023059 Ceased WO2021256540A1 (ja) 2020-06-19 2021-06-17 ウイルス不活化製剤

Country Status (2)

Country Link
JP (1) JP7509380B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021256540A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025135004A1 (ja) * 2023-12-22 2025-06-26 小林製薬株式会社 抗ウイルス剤

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06256129A (ja) * 1993-02-18 1994-09-13 Eiho Ko 無毒性消毒剤
US6066670A (en) * 1994-06-08 2000-05-23 Brown; Raymond K. Therapeutic compositions and methods of use
US20010053378A1 (en) * 1999-01-20 2001-12-20 John Chilakos Antiviral fumaric acid composition
US20070280901A1 (en) * 2006-06-02 2007-12-06 The Dial Corporation Method of inhibiting the transmission of influenza virus
JP2015168637A (ja) * 2014-03-06 2015-09-28 株式会社J−ケミカル 抗ウイルス用組成物
WO2020090545A1 (ja) * 2018-10-31 2020-05-07 富士フイルム株式会社 組成物、スプレー、ワイパー
CN111213786A (zh) * 2020-01-14 2020-06-02 山东信得科技股份有限公司 一种防控非洲猪瘟的水质酸化剂及其制备方法和应用
CN111557938A (zh) * 2020-05-20 2020-08-21 武汉齿欣生物医药科技有限责任公司 一种快速损伤病毒囊膜的消毒制剂
JP2020180082A (ja) * 2019-04-25 2020-11-05 セッツ株式会社 ノロウイルス感染抑制剤、消毒剤及び洗浄剤
WO2020245573A1 (en) * 2019-06-04 2020-12-10 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06256129A (ja) * 1993-02-18 1994-09-13 Eiho Ko 無毒性消毒剤
US6066670A (en) * 1994-06-08 2000-05-23 Brown; Raymond K. Therapeutic compositions and methods of use
US20010053378A1 (en) * 1999-01-20 2001-12-20 John Chilakos Antiviral fumaric acid composition
US20070280901A1 (en) * 2006-06-02 2007-12-06 The Dial Corporation Method of inhibiting the transmission of influenza virus
JP2015168637A (ja) * 2014-03-06 2015-09-28 株式会社J−ケミカル 抗ウイルス用組成物
WO2020090545A1 (ja) * 2018-10-31 2020-05-07 富士フイルム株式会社 組成物、スプレー、ワイパー
JP2020180082A (ja) * 2019-04-25 2020-11-05 セッツ株式会社 ノロウイルス感染抑制剤、消毒剤及び洗浄剤
WO2020245573A1 (en) * 2019-06-04 2020-12-10 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof
CN111213786A (zh) * 2020-01-14 2020-06-02 山东信得科技股份有限公司 一种防控非洲猪瘟的水质酸化剂及其制备方法和应用
CN111557938A (zh) * 2020-05-20 2020-08-21 武汉齿欣生物医药科技有限责任公司 一种快速损伤病毒囊膜的消毒制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025135004A1 (ja) * 2023-12-22 2025-06-26 小林製薬株式会社 抗ウイルス剤

Also Published As

Publication number Publication date
JPWO2021256540A1 (cg-RX-API-DMAC7.html) 2021-12-23
JP7509380B2 (ja) 2024-07-02

Similar Documents

Publication Publication Date Title
WO2009084211A1 (ja) 殺菌消毒剤組成物およびこれを含有する殺菌消毒材、ならびにこれらを用いた殺菌消毒方法
US7578970B2 (en) Methods of inhibiting growth of microorganisms using disinfectant compositions comprising orange oil mixtures
US20120121679A1 (en) Viricidal and microbicidal compositions and uses thereof
CN103068225B (zh) 可稀释的杀生物组合物和使用方法
JP5832201B2 (ja) 殺ノロウイルス組成物
JP6165953B1 (ja) ベシウイルス属ウイルス及び/又はノロウイルス属ウイルス用ウイルス不活性化剤及び衛生資材
GB2103089A (en) Use of carboxylic acids as virucides
US20240423202A1 (en) Antimicrobial composition
JP2014129372A (ja) カリシウイルス不活化方法
WO2011044916A1 (en) Multipurpose eco-friendly disinfecting composition comprising nano size antibacterial agent
JP6889925B2 (ja) ウイルス不活性化剤、ノロウイルス不活性化剤及び衛生資材
JP2019052107A (ja) 殺菌・ウイルス不活化剤及び殺菌・ウイルス不活化方法
JP2025081684A (ja) 洗浄剤組成物、スプレーボトル型洗浄剤、ウェットワイパー及び物品表面の洗浄方法
JP7509380B2 (ja) ウイルス不活化製剤
JP7824745B2 (ja) 抗ウイルス剤、消毒剤及び洗浄剤
JP7210190B2 (ja) 抗ノロウイルス剤、消毒剤及び洗浄剤
JP5377098B2 (ja) ノロウイルス不活性化剤
JP2018197222A (ja) ウイルス不活性化剤及び衛生資材
WO2022040135A1 (en) No rinse disinfectant with virucidal properties against non-enveloped viruses
WO2011015881A2 (en) Biocidal composition
Dickinson et al. Virucidal activities of novel hand hygiene and surface disinfectant formulations containing EGCG-palmitates (EC16)
WO2011009031A2 (en) Viricidal compositions and uses thereof
JP7080461B2 (ja) ウイルス不活性化剤、ノロウイルス不活性化剤及び衛生資材
JP2020033306A (ja) ノロウイルス不活性化剤及び衛生資材
Torko The efficacy of foam-based hand sanitizers for the control of enveloped and non-enveloped virus transmission

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2021561857

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21827055

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21827055

Country of ref document: EP

Kind code of ref document: A1